McKesson Q2 revenue slightly beats estimates, helped by increased prescription volumes
MCK•McKesson’s fiscal second-quarter revenue rose 8% to $110.96 billion, slightly above estimates, while adjusted EPS climbed 18% to $11.68, beating expectations. The company raised its fiscal 2027 adjusted EPS guidance to $45.60-$46.40 from $44.20-$45.00.
1. Quarterly results
McKesson reported fiscal second-quarter revenue of $110.96 billion, up 8% and slightly above the $109.88 billion analyst estimate. Adjusted EPS increased 18% to $11.68, beating the $10.70 estimate; adjusted net income was $1.36 billion.
2. Raised outlook
The company raised its fiscal 2027 adjusted EPS guidance to $45.60-$46.40 from $44.20-$45.00, and expects growth of 17% to 19% over the prior year.
3. Growth drivers
McKesson attributed revenue growth to increased prescription volumes and specialty product distribution in its North American Pharmaceutical and Oncology & Multispecialty segments. Adjusted EPS growth reflected operational growth across those segments and Prescription Technology Solutions, as well as a lower share count.
